Cargando…
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
SIMPLE SUMMARY: During the last two decades, collaborative translational studies utilizing novel methodologies have dramatically advanced our understanding of multiple myeloma (MM) pathophysiology and revolutionized derived treatment strategies. Nevertheless, MM remains an incurable disease, with th...
Autores principales: | Podar, Klaus, Leleu, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534171/ https://www.ncbi.nlm.nih.gov/pubmed/34680303 http://dx.doi.org/10.3390/cancers13205154 |
Ejemplares similares
-
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018) -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021) -
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022) -
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019) -
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
por: Bobin, Arthur, et al.
Publicado: (2021)